Brian Gastman, MD, discusses results from a biomarkers analysis of patients with stage IIB/C melanoma in the phase 3 CheckMate76K trial.
Brian Gastman, MD, Cleveland Clinic
Advertisement
Articles by Brian Gastman, MD, Cleveland Clinic
Advertisement
Latest Updated Articles
Balancing Safety and Efficacy in Adjuvant TherapyPublished: December 14th 2020 | Updated:
Adjuvant Clinical Trial Data Impact on Treatment SelectionPublished: December 14th 2020 | Updated:
Metastatic Melanoma Long-Term Survival DataPublished: December 14th 2020 | Updated:
Short-Term COVID-19 NCCN RecommendationsPublished: December 14th 2020 | Updated:
Impact of MSLT-II Data on Completion Lymph Node DissectionPublished: December 14th 2020 | Updated:
Emerging Treatments for Advanced MelanomaPublished: December 14th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5